Research News

Connecticut Children’s physicians recently co-authored an important study about a newly described inflammatory syndrome appearing in children across the nation 2-4 weeks after a COVID-19 infection or exposure. The syndrome has since been named multi-system inflammatory syndrome in children or MIS-C. There is now concern the number of these cases may rise given the latest spikes in infection rates in states in across the country.

This week, the U.S. Food and Drug Administration approved the world’s first gene therapy clinical trial for Glycogen Storage Disease (GSD).  This ground breaking clinical trial focusing on GSD Type Ia will be hosted by the GSD Program at Connecticut Children’s Medical Center and UConn Health under the direction of leading pediatric endocrinologist and scientist David Weinstein, MD, MMSc.

Thanks to an extraordinarily generous seven-figure gift from the Mandell-Braunstein family, the Center for Digestive Diseases at Connecticut Children’s Medical Center has established The Mandell-Braunstein Family Endowed Chair for Pediatric Inflammatory Bowel Disease. The gift will allow the Center for Pediatric Inflammatory Bowel Disease at Connecticut Children’s to expand both its research and clinical treatment efforts, which have already earned the Gastroenterology Division a designation as one of the best in the nation from U.S. News and World Report.

Connecticut Children’s is proud to announce that our own physician researcher, Glenn Flores, MD, played a direct role in drafting language for the recently passed Children’s Health Insurance Program (CHIP) re-authorization legislation.

Using a patient’s personal genetic makeup, a team of medical researchers led by a Connecticut Children’s gastroenterologist has discovered a new way to predict if a child newly diagnosed with Crohn’s disease will require major surgery within 3 to 5 years.